ABSTRACT: The anemia of chronic disease traditionally is defined as a hypoproliferative anemia of no apparent cause that occurs in association with an inflammatory, infectious, or neoplastic disorder, and resolves when the underlying disorder is corrected. Disordered iron metabolism as manifested by a low serum iron, decreased serum transferrin, decreased transferrin saturation, increased serum ferritin, increased reticuloendothelial iron stores, increased erythrocyte-free protoporphyrin, and reduced iron absorption, is a characteristic feature of the anemia of chronic disease and has been thought to be a major factor contributing to the syndrome. A mild shortening of red cell life span also occurs. However, we now know that impaired erythropoietin production and impaired responsiveness of erythroid progenitor cells to this hormone are also important abnormalities contributing to the anemia of chronic disease, and appear to be due to the effects of inflammatory cytokines. Increased intracellular iron may also have a role in the inhibition of erythropoietin production, since the oxygen sensor is a hemoprotein. While the role of inflammatory cytokines in the pathogenesis of anemia of chronic disease appears unequivocal, it has become apparent that disordered iron metabolism, while characteristic of this form of anemia, may not be central to its pathogenesis. It is undisputed that iron absorption is reduced, and that iron administered intravenously is rapidly sequestered in the reticuloendothelial system; however, iron delivery to the bone marrow is not impaired, and erythroid iron utilization is not markedly depressed in anemia of chronic disease. Importantly, recombinant erythropoietin therapy can correct the anemia of chronic disease, but it cannot correct the anemia due to iron deficiency. This refutes the concept that the lack of available iron is central to the pathogenesis of the syndrome. Indeed, it is highly likely that abnormalities such as reduced iron absorption and decreased erythroblast transferrin-receptor expression largely result from decreased erythropoietin production and inhibition of its activity by inflammatory cytokines. [ONCOLOGY 16(Suppl 10):25-33, 2002]
The anemia of chronic disease has been traditionally defined as a hypoproliferative anemia of no apparent cause associated with distinct abnormalities in iron metabolism. The syndrome occurs in the setting of an infectious, inflammatory, or neoplastic disorder and resolves when the underlying disorder is corrected (Figure 1). This form of anemia is thought to be a nonspecific consequence of the elaboration of inflammatory cytokines in response to the underlying systemic disorder.
The anemia of chronic disease can be normochromic and normocytic or hypochromic and microcytic. While the degree of hemoglobin reduction is usually modest, in some patients it can be severe (Figure 1). In keeping with its hypoproliferative nature, the reticulocyte count is low and the serum erythropoietin level, while elevated, is not increased to the extent seen in uncomplicated iron deficiency anemia or in hemolytic anemia. The leukocyte and platelet counts are either normal or increased depending on the nature of the underlying illness and the presence of associated complications. Bone marrow histology is usually normal except for increased iron stores. Typically, the amount of nonheme storage iron is increased at the expense of red cell iron.
The mechanisms for impaired erythropoiesis in the anemia of chronic disease are multifaceted and can be considered most easily in the context of the essential factors involved in erythropoiesis (Table 1). Since the major function of the red cell is to transport oxygen from the lungs to the other tissues, the process of red cell production is inextricably linked to tissue oxygenation—a linkage that has both positive and negative connotations. From the positive perspective, red cell production is coupled with long-term tissue oxygen needs by the glycoprotein hormone erythropoietin. In adults, erythropoietin is produced primarily in the kidneys and to only a small extent in the liver, and acts in the bone marrow to trigger dormant primitive red cells into entering the cell cycle and maintaining their viability as they differentiate into mature erythrocytes.
Because erythropoietin is an erythroid cell viability factor, its production must be constitutive, and because it is a mitogen, its production must be inducible, since it takes more erythropoietin to trigger a dormant erythroid cell into cycle than to maintain its viability. This contention is based on the difference between the numbers of erythropoietin receptors on primitive erythroid progenitors as compared with their more mature counterparts and corresponding erythropoietin dose-response curves for both types of progenitor cells. Because primitive erythroid progenitor cells have fewer erythropoietin receptors, a higher concentration of erythropoietin is required to ensure that ligand-receptor interactions take place.
Mechanisms of Erythropoietin Production
Under normal circumstances, the plasma erythropoietin level is constant in a given individual, just as that individual’s red cell mass is constant. With tissue hypoxia, there is recruitment of additional cells in the kidney to produce erythropoietin and to a smaller extent, up-regulation of erythropoietin production in hepatocytes.
Several feedback mechanisms ensure that red cell production matches tissue oxygen requirements. First, erythropoietin is metabolized by its target cells,[12,13] ensuring that erythropoiesis cannot exceed its stimulus. Second, as expansion of the red cell mass enhances tissue oxygenation, erythropoietin production is down-regulated. Third, as the red cell mass increases, plasma viscosity increases by an unknown mechanism, and this also down-regulates erythropoietin production. There also appears to be a threshold hemoglobin level (10.5 g/dL) above which plasma erythropoietin does not increase outside the range of normal. However, since the normal range for plasma erythropoietin is wide, 4 to 26 mU/mL, there is substantial latitude for a significant increase in the plasma erythropoietin level without exceeding the upper limit of normal.
Although tissue hypoxia is the only physiologic mechanism for increasing erythropoietin production, the plasma erythropoietin level is not always an accurate surrogate for this situation. This is because other factors such as intrinsic renal disease, liver disease, inflammatory cytokines,[16,17] or chemotherapy can influence erythropoietin production or its metabolism (Table 2). In the anemia of chronic disease, erythropoietin production (as reflected by its plasma level) is usually inappropriately low for the degree of anemia due to the effects of inflammatory cytokines.[16,17]
An adequate response to erythropoietin requires a normal complement of responsive erythroid progenitor cells. In the anemia of chronic disease, however, erythropoietin progenitor cell proliferation is suppressed both directly by inflammatory cytokines and indirectly through the inhibition of erythropoietin production by these cytokines.[16,17] An adequate supply of nutrients is also vital for effective erythropoiesis. These include amino acids, vitamins such as folic acid, B6, B12, and iron.
Patients with the anemia of chronic disease are often in a net catabolic state as evidenced by a reduction in the plasma level of albumin and transferrin, but the most important nutritional deficit involves iron—the absorption and distribution of which are profoundly altered in this situation. Finally, a mild shortening of red cell life span that appears to be extrinsic to the red cell has been documented in patients with anemia of chronic disease,[1,18] a defect for which a normally functioning marrow should easily compensate but does not in this circumstance. The situation is usually aggravated, particularly if the identity of the underlying disorder is in doubt, by the large volumes of blood removed for diagnostic testing.
Abnormalities in iron metabolism are a striking clinical feature of the anemia of chronic disease (Table 3), and have been considered not only diagnostic for its presence, but also central to the pathogenesis of the anemia.[19-21] However, as discussed below, neither of these contentions are supported by experimental and clinical observations. The abnormalities in iron metabolism, like the anemia, are partly a consequence of the inflammatory cytokine response and partly a consequence of the anemia.[1,22,23]
Iron is a vital mineral in cellular homeostasis, being essential for oxygen transport, DNA synthesis, and energy metabolism. Iron also represents a potential threat to cell function and tissue integrity, however, since oxidation of hemoglobin iron prevents oxygen release and leads to hemoglobin denaturation, while free iron promotes the synthesis of toxic oxygen radicals that can damage protein, lipids, and DNA. Furthermore, iron is vital for the proliferation of microbial organisms. Thus, iron metabolism is carefully controlled from its absorption in the intestine through its transport in the circulation and its uptake, utilization, and storage within various organs. Figure 2 provides an overview of iron transport pathways and distribution in adults under normal circumstances, and Figure 3 illustrates the salient features of iron absorption.
Central to the absorption, transport, and distribution of iron within the body are a group of proteins that have only recently been identified and whose functions are incompletely characterized. These proteins include the iron transport protein transferrin and the two forms of its cellular receptor, the iron storage protein ferritin, and the hemochromatosis protein (Hfe) that appears to regulate the affinity of the transferrin receptor for transferrin and the iron regulatory proteins (IRP) IRP1 and IRP2 that control the synthesis of ferritin and the transferrin receptor, divalent metal transporter DMT1 and metal transporter MTP1 that transport iron into and out of duodenal epithelial cells, respectively. Hephaestin, a membrane-bound ferroxidase, and hepcidin, an acute-phase reactant, stimulate cellular iron uptake.
The iron required to replace obligate losses due to desquamation of epithelial cells from the skin, gastrointestinal tract, and genitourinary tract; from bile, urine, and sweat; and from menstrual blood loss in women, is obtained from dietary intake in the form of heme and nonheme iron. Heme iron is easily absorbed without modification, but nonheme ferric iron requires chelation to amino acids, ascorbic acid, or sugars in the acid environment of the stomach for its absorption in the alkaline environment of the duodenum, where in the absence of chelation it would be converted to insoluble ferric hydroxides. Chelated ferric3+ iron is reduced to ferrous2+ by a ferrireductase in the brush border of duodenal epithelial cells before transport into these cells by the apical (lumenal) transporter DMT1.
The uptake and processing of dietary nonheme iron by duodenal epithelial cells represent the essential regulatory mechanisms for body iron balance: Body iron stores can only be adjusted by iron absorption because there is no normal mechanism for iron excretion. Therefore, duodenal enterocytes are programmed during their development in the duodenal crypts to facilitate or retard dietary iron absorption.[26,27] Although the details of this programming mechanism are not completely defined, multiple humoral regulatory pathways appear to be involved. These include a "stores" regulator that senses when body iron stores fall below a specific level, an "erythropoietic" regulator that senses an imbalance between the rate of erythropoiesis and the supply of iron, and an independent hypoxia regulator.[25,69] In addition to these humoral regulators, iron absorption appears to be subject to regulation by the relative concentrations of the specific proteins involved in iron transport and storage. These include the Hfe protein, the transferrin receptor, DMT1, MTP1, ferritin, and the acute-phase reactant hepcidin.
1. Cartwright GE: The anemia of chronic disorders. Semin
Hematol 3:351-375, 1966.
2. Means RT, Krantz SB: Progress in understanding the
pathogenesis of the anemia of chronic disease. Blood 80:1639-1647, 1992.
3. Spivak JL: The clinical physiology of erythropoietin. Semin
Hematol 30(4 suppl 6):2-11, 1993.
4. Baynes RD, Flax H, Bothwell TH, et al: Haematological and
iron-related measurements in active pulmonary tuberculosis. Scand J Haematol
5. Jacobson LO, Goldwasser E, Fried W, et al: Role of the
kidney in erythropoiesis. 1957. J Am Soc Nephrol 11:589-590, 2000.
6. Tan CC, Eckardt KU, Firth JD, et al: Feedback modulation
of renal and hepatic erythropoietin mRNA in response to graded anemia and
hypoxia. Am J Physiol 263(3 pt 2):F474-F481, 1992.
7. Koury MJ, Bondurant MC: A survival model of erythropoietin
action. Science 248:378-381, 1992.
8. Sawada K, Krantz SB, Dai CH, et al: Purification of human
blood burst-forming units-erythroid and demonstration of the evolution of
erythropoietin receptors. J Cell Physiol 142:219-230, 1990.
9. Eaves CJ, Eaves AC: Erythropoietin (Ep) dose-response
curves for three classes of erythroid progenitors in normal human marrow and in
patients with polycythemia vera. Blood 52:1196-1210, 1978.
10. Koury ST, Koury MJ, Bondurant MC, et al: Quantitation of
erythropoietin-producing cells in kidneys of mice by in situ hybridization:
Correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin
concentration. Blood 74:645-651, 1989.
11. Koury ST, Bondurant MC, Koury MJ, et al: Localization of
cells producing erythropoietin in murine liver by in situ hybridization. Blood
12. Sawyer ST, Krantz SB, Goldwasser E: Binding and
receptor-mediated endocytosis of erythropoietin in Friend virus-infected
erythroid cells. J Biol Chem 262:5554-5562, 1987.
13. Cazzola M, Guarnone R, Cerani P, et al: Red blood cell
precursor mass as an independent determinant of serum erythropoietin level. Blood
14. Singh A, Eckardt KU, Zimmermann A, et al: Increased
plasma viscosity as a reason for inappropriate erythropoietin formation. J
Clin Invest 91:251-256, 1993.
15. Miller CB, Jones RJ, Zahurak ML, et al: Impaired
erythropoietin response to anemia after bone marrow transplantation. Blood
16. Faquin WC, Schneider TJ, Goldberg MA: Effect of
inflammatory cytokines on hypoxia-induced erythropoietin production. Blood
17. Jelkmann W, Pagel H, Wolff M, et al: Monokines inhibiting
erythropoietin production in human hepatoma cultures and in isolated perfused
rat kidneys. Life Sci 50:301-308, 1992.
18. Dinant HJ, de Maat CE: Erythropoiesis and mean red-cell
lifespan in normal subjects and in patients with the anaemia of active
rheumatoid arthritis. Br J Haematol; 39:437-444, 1978.
19. Weiss G: Iron and anemia of chronic disease. Kidney
Int Suppl; 69:S12-S17, 1978.
20. Jurado RL: Iron, infections, and anemia of inflammation. Clin
Infect Dis 25:888-895, 1997.
21. Freireich E, Miller A, Emerson CP, et al: The effect of
inflammation on the utilization of erythrocyte and transferrin bound radioiron
for red cell production. J Hemat 12:11, 1957.
22. Lukens JN: Control of erythropoiesis in rats with
adjuvant-induced chronic inflammation. Blood 41:37-44, 1973.
23. Zarrabi MH, Lysik R, DiStefano J, et al: The anaemia of
chronic disorders: Studies of iron reutilization in the anaemia of experimental
malignancy and chronic inflammation. Br J Haematol 35:647-658, 1977.
24. Kluger MJ, Rothenburg BA: Fever and reduced iron: Their
interaction as a host defense response to bacterial infection. Science
25. Andrews NC: Disorders of iron metabolism. N Engl J Med
26. Roy CN, Enns CA: Iron homeostasis: New tales from the
crypt. Blood 96(4020-4027, 1999.
27. Fleming RE, Sly WS: Hepcidin: A putative iron-regulatory
to hereditary hemochromatosis and the
anemia of chronic disease. Proc Natl Acad Sci U S A 98:8160-8162, 2001.
28. Schade SC: Effect of hydrochloric acid on iron
absorption. N Engl J Med 279:672-674, 1968.
29. Ponka P: Cellular iron metabolism. Kidney Int Suppl
30. Eisenstein RS: Iron regulatory proteins and the molecular
control of mammalian iron metabolism. Annu Rev Nutr 20:627-662, 2000.
31. Recalcati S, Taramelli D, Conte D, et al: Nitric
oxide-mediated induction of ferritin synthesis in J774 macrophages by
inflammatory cytokines: Role of selective iron regulatory protein-2
downregulation. Blood 91:1059-1066, 1998.
32. Weiss G, Bogdan C, Hentze MW: Pathways for the regulation
of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13.
J Immunol 158:420-425, 1997.
33. Wang GL, Semenza GL: Desferrioxamine induces
erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding
activity: Implications for models of hypoxia signal transduction. Blood
34. Ho VT, Bunn HF: Effects of transition metals on the
expression of the erythropoietin gene: Further evidence that the oxygen sensor
is a heme protein. Biochem Biophys Res Commun 223:175-180, 1996.
35. Daghman NA, McHale CM, Savage GM, et al: Regulation of
erythropoietin gene expression depends on two different oxygen-sensing
mechanisms. Mol Genet Metab 67:113-117, 1999.
36. Kling PJ, Dragsten PR, Roberts RA, et al: Iron
deprivation increases erythropoietin production in vitro, in normal subjects and
patients with malignancy. Br J Haematol 95:241-248, 1996.
37. Salvarani C, Baricchi R, Lasagni D, et al: Effects of
desferrioxamine therapy on chronic disease anemia associated with rheumatoid
arthritis. Rheumatol Int 16:45-48, 1996.
38. Polson RJ, Jawad AS, Bomford A, et al: Treatment of
rheumatoid arthritis with desferrioxamine. QJM 61:1153-1158, 1986.
39. Weiss G, Houston T, Kastner S, et al: Regulation of
cellular iron metabolism by erythropoietin: Activation of iron-regulatory
protein and upregulation of transferrin receptor expression in erythroid cells. Blood
40. Tong X, Kawabata H, Koeffler HP: Iron deficiency can
upregulate expression of transferrin receptor at both the mRNA and protein
level. Br J Haematol 116:458-464, 2002.
41. Nordstrom D, Lindroth Y, Marsal L, et al: Availability of
iron and degree of inflammation modifies the response to recombinant human
erythropoietin when treating anemia of chronic disease in patients with
rheumatoid arthritis. Rheumatol Int 17:67-73, 1997.
42. O’Toole PA, Sykes H, Phelan M, et al: Duodenal mucosal
ferritin in rheumatoid arthritis: Implications for anaemia of chronic disease. QJM
43. Raymond FD, Bowie MA, Dugan A: Iron metabolism in
rheumatoid arthritis. Arthr Rheum 8:233-243, 1965.
44. Savage D, Lindenbaum J: Anemia in alcoholics. Medicine
(Baltimore) 65:322-338, 1986.
45. Douglas SW, Adamson JW: The anemia of chronic disorders:
Studies of marrow regulation and iron metabolism. Blood 45:55-65, 1975.
46. Moldawer LL, Marano MA, Wei H, et al: Cachectin/tumor
necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo.
FASEB J 3:1637-1643, 1975.
47. Lappin MB, Campbell JD: The Th1-Th2 classification of
cellular immune responses: Concepts, current thinking and applications in
haematological malignancy. Blood Rev 14:228-239, 2000.
48. Graziadei I, Gaggl S, Kaserbacher R, et al: The
acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of
human early erythroid progenitor cells (burst-forming units-erythroid) and of
human erythroleukemic cells (K562) in vitro by interfering with transferrin iron
uptake. Blood 83:260-268, 1994.
49. Tong X, Kawabata H, Koeffler HP: Iron deficiency can
upregulate expression of transferrin receptor at both the mRNA and protein
level. Br J Haematol 116:458-464, 2002.
50. Fleming RE, Migas MC, Holden CC, et al: Transferrin
receptor 2: Continued expression in mouse liver in the face of iron overload and
in hereditary hemochromatosis. Proc Natl Acad Sci U S A 97:2214-2219,
51. Van Snick JL, Masson PL: The binding of human lactoferrin
to mouse peritoneal cells. J Exp Med 144:1568-1580, 1976.
52. Baynes R, Bezwoda W, Bothwell T, et al: The non-immune
inflammatory response: Serial changes in plasma iron, iron-binding capacity,
lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest
53. Hellwig-Burgel T, Rutkowski K, Metzen E, et al:
Interleukin-1 beta and tumor necrosis factor-alpha stimulate DNA binding of
hypoxia-inducible factor-1. Blood 94:1561-1567, 1999.
54. Jelkmann W: Proinflammatory cytokines lowering
erythropoietin production. J Interferon Cytokine Res 18:555-559,
55. Means RT, Krantz SB: Inhibition of human erythroid
colony-forming units by tumor necrosis factor requires beta interferon. J
Clin Invest 91: 416-419, 1993.
56. Means RT, Dessypris EN, Krantz SB: Inhibition of human
erythroid colony-forming units by interleukin-1 is mediated by gamma interferon.
J Cell Physiol 150:59-64, 1992.
57. Taniguchi S, Dai CH, Price JO, et al: Interferon gamma
downregulates stem cell factor and erythropoietin receptors but not insulin-like
growth factor-I receptors in human erythroid colony-forming cells. Blood
58. Maciejewski JP, Selleri C, Sato T, et al: Nitric oxide
suppression of human hematopoiesis in vitro. Contribution to inhibitory action
of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest
59. Johnson CS, Cook CA, Furmanski P: In vivo suppression of
erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): Reversal with
exogenous erythropoietin (EPO). Exp Hematol 18:109-113, 1990.
60. Means RT, Krantz SB: Inhibition of human erythroid
colony-forming units by gamma interferon can be corrected by recombinant human
erythropoietin. Blood 78:2564-2567, 1991.
61. Pincus T, Olsen NJ, Russell IJ, et al: Multicenter study
of recombinant human erythropoietin in correction of anemia in rheumatoid
arthritis. Am J Med 89:161-168, 1990.
62. Pettersson T, Rosenlof K, Laitinen E, et al: Effect of
exogenous erythropoietin on haem synthesis in anaemic patients with rheumatoid
arthritis. Br J Rheumatol 33:526-529, 1994.
63. Kaltwasser JP, Kessler U, Gottschalk R, et al: Effect of
recombinant human erythropoietin and intravenous iron on anemia and disease
activity in rheumatoid arthritis. J Rheumatol 28:2430-2436, 2001.
64. Vreugdenhil G, Baltus JA, van Eijk HG, et al: Prediction
and evaluation of the effect of iron treatment in anaemic RA patients. Clin
Rheumatol 8:352-362, 1989.
65. Feelders RA, Vreugdenhil G, van Dijk JP, et al: Decreased
affinity and number of transferrin receptors on erythroblasts in the anemia of
rheumatoid arthritis. Am J Hematol 43:200-204, 1993.
66. Cazzola M, Ponchio L, de Benedetti F, et al: Defective
iron supply for erythropoiesis and adequate endogenous erythropoietin production
in the anemia associated with systemic-onset juvenile chronic arthritis. Blood
67. Spivak JL: The blood in systemic disorders. Lancet
68. Cash JM, Sears DA: The anemia of chronic disease:
Spectrum of associated diseases in a series of unselected hospitalized patients.
Am J Med 87:638-644, 1989.
69. Finch C: Regulators of iron balance in humans. Blood
70. Kurnick JE, Ward HP, Pickett JC: Mechanism of the anemia
of chronic disorders: Correlation of hematocrit value with albumin, vitamin B
12, transferrin, and iron stores. Arch Intern Med 130:323-326, 1972.
71. Nordstrom D, Lindroth Y, Marsal L, et al: Availability of iron and degree
of inflammation modifies the response to recombinant human erythropoietin when
treating anemia of chronic disease in patients with rheumatoid arthritis. Rheumatol
Int 17:67-73, 1997.